Prospective study of continuous rhythm monitoring in patients with early post-infarction systolic dysfunction: clinical impact of arrhythmias detected by an implantable cardiac monitoring device with real-time transmission-the TeVeO study protocol. [PDF]
Hernandez-Hernandez J+21 more
europepmc +1 more source
E. Ammirati+45 more
semanticscholar +1 more source
Cardiac Dysfunction and Subclinical Atherosclerosis in Post-COVID-19 Patients. [PDF]
Cozma A+14 more
europepmc +1 more source
ABSTRACT Background Transcatheter pulmonary valve replacement (TPVR) has emerged as a valuable treatment for severe pulmonary regurgitation (PR). The Salus valve (Balance Medical Technology Co. Ltd., Beijing, China) represents a novel self‐expanding valve stent designed for deployment through a transthoracic approach with a small subxiphoid incision ...
Ziqin Zhou+6 more
wiley +1 more source
Diagnostic value of lung ultrasound B-lines for evaluating left ventricular filling pressure. [PDF]
Sakamoto T+7 more
europepmc +1 more source
ABSTRACT Background Diabetes mellitus (DM) is a well‐known risk factor for cardiovascular diseases, including coronary artery diseases (CAD). Complex percutaneous coronary intervention (PCI) such as PCI for bifurcation lesions often yields poor outcomes, especially in DM patients.
Subin Lim+31 more
wiley +1 more source
Bilateral Venous Access for Cardiac Resynchronization Therapy in a Hemodialysis Patient With Cabozantinib-associated Heart Failure. [PDF]
Otoi A+19 more
europepmc +1 more source
Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease
L. Pacifico+6 more
semanticscholar +1 more source
ABSTRACT Background Little is known about the clinical and hemodynamic outcome of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) for failed Trifecta surgical aortic bioprotheses. Aims We aimed to compare outcomes of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR into failed TrifectaTM vs.
Matthias Raschpichler+9 more
wiley +1 more source
Dual ET<sub>A</sub>-ET<sub>B</sub> receptor antagonism improves metabolic syndrome-induced heart failure with preserved ejection fraction. [PDF]
Lockwood F+11 more
europepmc +1 more source